Digest Network Come funziona
Network
/
Società
Me
Non verificato

Merz Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

7 comunicati stampa

Guarda tutti i comunicati
26/01/2026
Salute
Vetrine/Shopping
Giovani
Infanzia
Farmaceutica
Industria
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity
Fonte
Merz Therapeutics
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 2026
Fonte
Merz Therapeutics
Emittente
Business Wire
1.00
0
25/08/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Merz Therapeutics Announces First Patients Enrolled in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention
Fonte
Merz Therapeutics
Emittente
Business Wire
1.00
0
17/12/2024
Industria
Attrezzature medico-sanitarie
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Health Canada Approves XEOMIN® (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot
Fonte
Merz Therapeutics
Emittente
Business Wire
1.00
0
24/10/2024
Mercato del lavoro
Responsabilità sociale d'impresa
Industria
Associazioni/Professionisti
Sanità
Biotecnologia
Farmaceutica
Salute
Merz Therapeutics and World Stroke Organization Launch ‘Access to Health’ Initiative to Improve Stroke Care in Africa
Fonte
Merz Therapeutics
Emittente
Business Wire
1.00
0
10/07/2024
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Fonte
Merz Therapeutics
Emittente
Business Wire
1.00
0
10/07/2024
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Fonte
Merz Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0